Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resminostat - 4SC

Next Previous
Drug Profile

Resminostat - 4SC

Alternative Names: 4SC-201; BYK-408740; Kinselby; RAS-2410; Resminostat-4-SC; YHI-1001

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nycomed
  • Developer 4SC; Yakult Honsha
  • Class Antineoplastics; Dimethylamines; Hydroxylamines; Pyrroles; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T-cell lymphoma; Hodgkin's disease; Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Biliary cancer; Cutaneous T-cell lymphoma; Hodgkin's disease; Liver cancer; Mycosis fungoides; Non-small cell lung cancer; Pancreatic cancer; Sezary syndrome
  • Phase I/II Colorectal cancer
  • No development reported Solid tumours
  • Discontinued Diffuse large B cell lymphoma

Most Recent Events

  • 22 Mar 2024 4SC announces intention for submitting filings in the UK and Switzerland in cutaneous T-cell lymphoma
  • 20 Dec 2023 4SC announces its intention to launch resminostat for the treatment of Cutaneous T-cell lymphoma in the Europe
  • 19 Oct 2023 4SC announces its intention to file for Marketing Approval for Cutaneous T-cell lymphoma (PO) in Switzerland and the United Kingdom
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top